ORDERING RELENZA — HOW TO ORDER RELENZA

Guideline 5: Distribution

A thorough discussion of the preferred option for timing of distribution and use of antivirals should be agreed upon and documented. Many options are available; some include:

• Distribution upon receiving RELENZA product
   
• When public health officials declare specified pandemic phase. Visit http://www.who.org for up-to-date pandemic information
   
• When predetermined events occur as outlined in your pandemic plan

Every organization should have its own plan regarding distribution. Consider all the logistics and challenges that need to be met to ensure your employees receive their assigned doses. During your organization’s pandemic planning phase, determine how you would coordinate the distribution of RELENZA from the storage location to your employees. Be sure to share this plan with your distributors and storage facility as well.

Guideline 6: Education

 
Important Safety Information About RELENZA

• Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
  
• RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
  
• Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions
  
• Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible
  
• If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
  
• Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups
  
• Please see complete Prescribing Information for RELENZA